July 27, 2020 + Jessica Di Palo
5 Min read
Venture Capital financing in Q1’20 will be the second steepest decline in the past 10 years according to data from CB Insights. Techtour interviewed our Managing Partner Christoph Kausch and 3 other investors to share their business priorities, how they adjusted their strategies and how are they helping their portfolio companies.
Tech Tour: How is the COVID-19 crisis impacting the funding landscape for startups?
Christoph Kausch: Like the rest of us, startups have not been exempt from the impacts of COVID-19. Some have benefited from the increased demand for technological solutions, enabling connectivity in light of social isolation. Other startups – in retail, for example – have clearly suffered. I think the hardest thing for both startups seeking finance, as well as investors, is the current state of uncertainty. There’s a general unwillingness to commit to new investments that aren’t “COVID-proof” right now when we don’t know how long this will all last. Many investors had already felt that startup valuations had been overflowing for some time now. In this respect, there has actually been evidence of better alignment between investors and management teams on finding the best solution to close the deal. There’s enough capital in the market to ensure that the best companies will still get funded. It just may take a bit more time than usual. It’s an obvious consequence that Investment Committees want to see additional diligence and risk assessments for COVID-19. I think it’s also very important now more than ever to support existing portfolio company management teams in their additional funding needs via both grant funding and additional capital injections if needed.
MTIP leads the €20 million growth financing round in LynxCare
Largest capital round ever in digital health in Belgium
Pioneering the use of machine learning algorithms to turbo-charge drug development
Intelligencia revolutionizes drug development
The psychology of decision making
What makes a good investor?
Revolutionizing medical triage with artificial intelligence
Mediktor's solution for medical triage
MTIP Closes Second Healthtech Growth Fund Above Target With $250M of Commitments
MTIP Fund II is closed!
Cynerio Now! – A new IoT cybersecurity solution for small hospitals and clinics
Cynerio's new product Cynerio Now!
MTIP invests in Mediktor
New investment in Mediktor
SFDR Art. 8 or Art. 9? What’s the difference?
SFDR: getting the terminology right
MTIP participates in Oviva’s new $80m Series C funding
Oviva raises $80 million financing round
MTIP invests in Intelligencia to reduce the risk of clinical research through artificial intelligence
MTIP's new investment in Intelligencia
Private Equity 101: Part one – Glossary
Are you new to the healthtech space?
Leading brands revolutionize care journeys with Lumeon
How Lumeon orchestrates care journey
Trialbee – our hero in patient matching and recruiting for clinical trials
Trialbee - patient matching and recruiting
Digital healthcare: patient-first?
Digital Healthcare Report 2021 in collaboration with Dealroom and INKEF Capital
SFDR – How does MTIP approach the EU’s Sustainable Disclosure Regulation?
New SFDR obligations
MTIP Announces Strong First Closing of Fund II to drive Healthtech Innovation
First Closing of Fund II
How to pitch to a healthtech Investor
MTIP invests in Koa Health to make mental health treatment more accessible
New investment in Koa Health
MTIP scored fantastic grades in the UNPRI assessment report of 2020
UNPRI Report grades 2020
4 Health VCs Share Their Business Priorities and What is Next
MTIP invests in Trialbee
New investment in Trialbee
TytoCare closes $50 million round as the demand for telehealth accelerates
TytoCare closes new round
The digital healthtech sector is expanding – and so are we!
Two new empolyees start in April
MTIP has sucessfully exited Blueprint Genetics
Blueprint exit January 2020
New MTIP investment in Oviva
New investment in Oviva